Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes.
Peng Yuan
No relevant relationships to disclose
Jiayu Wang
No relevant relationships to disclose
Fei Ma
No relevant relationships to disclose
Ying Fan
No relevant relationships to disclose
Yang Luo
No relevant relationships to disclose
Ruigang Cai
No relevant relationships to disclose
Pin Zhang
No relevant relationships to disclose
Qing Li
No relevant relationships to disclose
Binghe Xu
No relevant relationships to disclose